Invivyd, Inc. is a biopharmaceutical company that discovers, develops, and commercializes monoclonal antibody therapies for preventing and treating serious viral infectious diseases. The company's commercial product, PEMGARDA, is a half-life extended antibody that prevents COVID-19 in immunocompromised patients, distributed through specialty distributors and direct partnerships with healthcare providers, while its pipeline includes next-generation COVID-19 candidates and programs targeting RSV and measles. The company leverages a proprietary technology platform featuring antibody engineering capabilities, variant surveillance, and continuous improvement of antibody potency and half-life, generates revenue through commercial sales and manufacturing partnerships, and relies on an exclusive collaboration with Adimab for antibody discovery and engineering platform access.